Cargando…

CA 19-9 as a serum marker in urothelial carcinoma

INTRODUCTION: CA 19-9 is a carbohydrate antigen related to Lewis A blood group antigen. It is well-known marker for pancreatic carcinoma and is being investigated for other malignancies including carcinoma bladder. We evaluated the role of serum CA 19-9 as a tumor marker and correlated its level wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pall, Mahander, Iqbal, Javid, Singh, Shrawan Kumar, Rana, Satya Vati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355709/ https://www.ncbi.nlm.nih.gov/pubmed/22629005 http://dx.doi.org/10.4103/0974-7796.95555

Ejemplares similares

Primary Small Cell Carcinoma of Liver: A Rare Tumor
por: Kaman, Lileswar, et al.
Publicado: (2010)

Treatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study
por: Kaur, Ishwarpreet, et al.
Publicado: (2021)

Contrast enhanced ultrasound in urothelial carcinoma of urinary bladder: An underutilized staging and grading modality
por: Gupta, Vijayant Govinda, et al.
Publicado: (2016)

High serum levels of CA 19-9 and CYFRA21-1 caused by renal pelvis urothelial carcinoma: a report of two cases
por: Yin, Guolin, et al.
Publicado: (2021)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
por: Haglund, C., et al.
Publicado: (1986)

Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2
por: Rathi, Himani, et al.
Publicado: (2021)

Impacts of CA9 Gene Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Characteristics in Taiwan
por: Wang, Shian-Shiang, et al.
Publicado: (2013)

Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis
por: Sharma, Gopal, et al.
Publicado: (2021)

Assessment of quality of life in patients having Poly-Cystic Ovarian Syndrome: A cross-sectional facility-based study
por: Kaur, Ishwarpreet, et al.
Publicado: (2023)

Treatment seeking behavior among patients with polycystic ovarian syndrome (PCOS)—A cross-sectional study from Northern India
por: Kaur, Ishwarpreet, et al.
Publicado: (2023)

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
por: Wang, Wei, et al.
Publicado: (2016)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

Oncological markers CA-125, CA 19-9 and endometriosis
por: Fiala, Ludek, et al.
Publicado: (2018)

Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
por: Haglund, C., et al.
Publicado: (1991)

Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma
por: Vukobrat-Bijedic, Zora, et al.
Publicado: (2013)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer
por: Gao, Yanfeng, et al.
Publicado: (2018)

Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma
por: EDOO, Muhammad Ibrahim Alhadi, et al.
Publicado: (2019)

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma
por: Ross, R. L., et al.
Publicado: (2016)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Role of Systemic Inflammatory Response Markers in Urothelial Carcinoma
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Molecular markers of systemic therapy response in urothelial carcinoma
por: Claps, Francesco, et al.
Publicado: (2021)

Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma
por: Traeger, Lisa, et al.
Publicado: (2019)

Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
por: Dbouk, Mohamad, et al.
Publicado: (2023)

Raised CA19–9 and CEA have prognostic relevance in gallbladder carcinoma
por: Sachan, Ashish, et al.
Publicado: (2020)

Gallbladder motility in children with celiac disease before and after gluten-free diet
por: Das, Subhamoy, et al.
Publicado: (2021)

Serum CA(19-9) in patients with solid pancreatic mass
por: Baghbanian, Mahmud, et al.
Publicado: (2013)

Intralobar Pulmonary Sequestration and Increased Serum CA 19-9
por: Montalto, Massimo, et al.
Publicado: (2017)

Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study
por: Al-Shuneigat, Jehad M, et al.
Publicado: (2011)

Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
por: Stein, Barbara, et al.
Publicado: (2013)

Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients
por: Zhao, Jia-Xing, et al.
Publicado: (2017)

Diagnostic Significance of Serum IgG Galactosylation in CA19-9-Negative Pancreatic Carcinoma Patients
por: Zhong, Ailing, et al.
Publicado: (2019)

Occult scar carcinoma of the lung with overt liver metastases and high serum CA 19-9 levels
por: Lin, YY, et al.
Publicado: (2019)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant
por: Liu, Wei, et al.
Publicado: (2018)

Diagnostic values of serum tumor markers Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in oral/oropharyngeal squamous cell carcinoma
por: Yuan, Chuanshu, et al.
Publicado: (2016)

Colorectal Carcinoma with Extremely Low CA19-9
por: Kawamura, Yutaka J., et al.
Publicado: (2009)

Metastatic papillary thyroid carcinoma presenting with elevated serum levels of carbohydrate antigen 19-9 (CA19-9): a case report
por: Kihara, Minoru, et al.
Publicado: (2022)

The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control
por: Shang, Xiaojing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rro1gub97iifcp2sufrops9do7